AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
Wegoreddirt - Author Avatar

Wegoreddirt

Wegoreddirt
Wegoreddirt 3h ago
$CELH weak hands lose moneyCELH--
Wegoreddirt
Wegoreddirt 4h ago
Shorted $NUGT at 117.60NUGT--
Wegoreddirt
Wegoreddirt 13h ago
$SPY let’s open 742SPY--
CoinbaseCorner
CoinbaseCorner 13h ago

Rates steady, liquidity intact; SPY open reflects risk-on tone.

Lorien6
Lorien6 13h ago

I’m cautiously optimistic, but I’m trimming tech and adding a bit of cash until we confirm a real move.

Last-Care6342
Last-Care6342 13h ago

SPY open 742; 50-day is 740. Momentum looks intact.

Wegoreddirt
Wegoreddirt Yesterday
$RDDT back on our watch as it starts to form a base Fundamentals are still solid but slow growth in active users is keeping the stock down Check out Income Flow Chart below
post-image-1024b27fb8107e34f451
RDDT--
CuddleBuddiesJJ
CuddleBuddiesJJ Yesterday

Seen this movie with other social tokens before—strong fundamentals, weak traction, and sentiment rallies fade. Feels like a trap.

Sjgreen
Sjgreen Yesterday

I’m on the sidelines here. The base looks nice, but slow user growth and thin liquidity make me nervous. If $RDDT can’t show real engagement spikes or revenue traction, I’d rather wait.

Puzzleheadbrisket
Puzzleheadbrisket Yesterday

For those holding long, what’s the realistic path to growth? Are they monetizing ads, subscriptions, or partnerships, and how does that compare to $SNAP or $TWT?

Wegoreddirt
Wegoreddirt Yesterday
$SLS Confirm 1 Million WT1+ Patients Diagnosed Annually Share Price Could Hit $200 Still Leaves $LLY Big Upside $MRNA $XBILLY--
MRNA--
XBI--
SLS--
Bruegemeister
Bruegemeister 11h ago

Everyone cheering $SLS hitting 200, but catalysts fade fast. Watching volume and breadth before chasing.

yungdjtechno
yungdjtechno 11h ago

For those holding long term, how do you weigh the 1M patient milestone against ongoing regulatory hurdles and payer adoption? If $SLS scales, what's the realistic 5-year multiple versus $LLY and $MRNA?

eudaimonia_dc
eudaimonia_dc 12h ago

SLS hitting 1M WT1+ patients annually is a big deal, but I'm cautious about the $200 target without clearer revenue timelines. If they hit 10% market share, $LLY could still run, but $MRNA's moat feels wider.

Wegoreddirt
Wegoreddirt Yesterday
$INTC $54.50 was solidINTC--
Minimac1029
Minimac1029 Yesterday

From an allocation view, I’m keeping tech at 25% and trimming cyclicals. $INTC fits as a core holding, but I’m adding only on pullbacks near support, not chasing.

OGBobtheflounder
OGBobtheflounder Yesterday

Cloud sector feels okay, but I’m cautious on comps.

Jasonphos
Jasonphos Yesterday

Is this really 'solid' when margins and guidance look flat? Could be a pullback if cloud growth cools.

Wegoreddirt
Wegoreddirt Yesterday
$SOFI You're the woke one FalseSetup2!SOFI--
Wegoreddirt
Wegoreddirt 11/16
$SKHY hit a new low today which seems really negative. Could be a sign or a trick. Reminds me of $SOXS reaching $20s in early October. It looked bad, but turned out to be the start of something great. $KORU $MU $SOXXKORU--
MU--
SKHY--
SOXS--
SOXX--
Wegoreddirt
Wegoreddirt 11/16
$MSFT credit is wondering about equity. It seems like pricier debt for data centers changes the return math even for the top company in the buildMSFT--
PlunderGang
PlunderGang 11/16

I’m long MSFT and a bit of AMZN; does pricier debt pressure cash flow enough to offset cloud growth?

Masala-Papad
Masala-Papad 11/16

WACC up 100 bps? EPS growth can’t keep pace.

ThatUnoriginalGuy
ThatUnoriginalGuy 11/16

Seen this movie in 2018 and 2022: cheap equity, expensive debt. If MSFT’s WACC rises, margins can’t save them.

Wegoreddirt
Wegoreddirt 11/16
$SLS Just Do The Math Why Did $MRNA Jump $40B in Market Value After Its P3 Cancer Vaccine Results Were Announced For All the Same Reasons $SLS Is Going To And Up Nearly $100B Since From $22 to $280 DO THE MATH Unmet Need Zero Competition 50,000 AML Remission Patients Each Year 2x 4x OS Advantage PRISTINE SAFETY PROFILE Easy SubQ at Home Administration IP RIGHTS until 2037 FDA EU Fast Track Orphan Designation $MRNA $XBI
post-image-1024b077be16ee02a77d
MRNA--
SLS--
XBI--
EmergencyWitness7
EmergencyWitness7 11/16

Are we sure this isn’t just early data? What’s the sample size, and how do they compare to existing AML treatments?

OhShit__ItsDrTran
OhShit__ItsDrTran 11/16

Trend looks unstoppable; momentum traders probably riding this wave.

WorgenFurry
WorgenFurry 11/16

Everyone cheering the headline, but I’m not convinced. Market cap jumps can fade if follow-through data is weak. If $MRNA stalls on volume or $SLS retests highs, I’m trimming and waiting for a pullback.

Scroll to load more